



A phase III randomised, triple-blind controlled superiority trial of remimazolam (CNS 7056), compared to midazolam, in adults having lower third molar wisdom tooth extraction under intravenous conscious sedation to assess cognitive and motor recovery at normal discharge times.

Short title:

Remimazolam vs midazolam cognitive and motor recovery after intravenous conscious sedation for dental extractions.

Study Acronym:

REMIDENT

Remident Summary Trial Patient Information Leaflet

Remident Summary Trial Patient Information Leaflet

IRAS Number: 1003587 Version Number: v1.2

EudraCT Number: 2020-005121-89





The Diagram below summarises the trial procedures:



Read Patient Information Leaflet

2



Receive call from doctor and discuss the trial, any questions or concerns

3 Appointment Day



Pre- sedation Questionnaires & Tests



Dental Sedation & wisdom tooth removal



Post sedation Questionnaires & Tests

4



Follow up phone call

Remident Summary Trial Patient Information Leaflet

IRAS Number: 1003587 Version Number: v1.2

EudraCT Number: 2020-005121-89





Summary Patient Information Leaflet

Aim of the research

We want to know if a new drug that is used to sedate and relax patients having dental treatment is better than the current drug we use. We think the new drug will allow patients to recover faster and feel better quicker after surgery.

Background to the research

A lot of people worry about dental treatment. We know that over 12% of people in Britain are very anxious about dental work. Having teeth removed is often said to cause the most anxiety.

Intravenous sedation is where a drug is injected into a patient's hand or arm. The drug stops them feeling worried, helps them relax and better able to cope. About half a million sedations for dental treatment are carried out in England each year. Sedation is very safe, and people generally say that they have had a good experience.

After sedation patients wait in a recovery area until they are safe to walk. They usually go home after about an hour, but the side effects of the drug can last until the next day. This can cause people to forget important things, like putting a cooker on, and to feel heavy and sleepy and risk bumping into things for the rest of the day.

A new drug is in development that has the same sedation effect and safety, but the recovery is much quicker. We think that the side effects from the new drug will have worn off by the time patients are ready to leave the hospital. This means patients might feel more alert going home and better able to look after themselves.

How will the research be carried out?

We want to carry out a blinded randomised controlled trial. Randomisation means that Patients are randomly picked by a computer to be given the new or old drug. This is recommended as the best way to test if a drug is better. The research team and the patient do not know which drug is used. This is so that they cannot influence the result.

Who will be included?

Remident Summary Trial Patient Information Leaflet

IRAS Number: 1003587 Version Number: v1.2

EudraCT Number: 2020-005121-89





We will ask patients who are coming to Guy's Hospital to have their wisdom tooth extracted under sedation if they want to be included in the research. They will be given an information about the trial by the clinical team and a leaflet. They will be given at least 24 hours to think about it before one of the research team phones them to see if they have any other questions and want to be included.

What will happen if you participate?

On the day of the appointment you will be asked to follow all the normal sedation instructions. The sedation and dental treatment will be carried out in the normal way. The only extra things that you will be asked to do will be some questionnaires and some tests. This will add an extra 2 hours to your appointment time. You will only be discharged on the day of the procedure with an accompanying person.

There are 4 research tests:

- Learning test
 - You will be asked to listen to some words and repeat them back. This tests how well you can remember new information
- 2) Reaction test
 - You will be asked to rest your fingers on a keypad and move your fingers when lights come on above them. This tests how quick your reactions are.
- 3) Symbol test
 - You will be asked to draw small shapes that linked to numbers. This tests how well you can process information.
- 4) Standing test
 - You will be asked to stand on a platform that measures how much you are swaying back and forth. This tests how stable you are to walk.

These tests are designed to check different ways the brain and body are affected by the sedation. By testing people before and after the sedation we can see how they recovered. We then will check the results of the new and existing drugs to see if people having the new drug recovered quicker.

We plan to phone patients a few days after their appointment to check they were happy with the sedation. We will also check they did not have any side effects from the medication. The phone call will take about 20 minutes.

A reimbursement up to £60 will made to you to cover reasonable expenses including travel expenses for yourself and your accompanying person.

Normal fasting instructions will be given to you by the doctor and standard of care leaflets. As part of normal post-operative instructions you will be are asked to refrain from alcohol,

Remident Summary Trial Patient Information Leaflet

IRAS Number: 1003587 Version Number: v1.2

EudraCT Number: 2020-005121-89





using heavy machinery, making important decisions or taking non-prescription drugs for at least 24 hours following the procedure. Post-operative analgesics like paracetamol may be recommended by the doctor as per standard of care.

How will we use information about you?

We will need to use information from your medical records for this research project.

This information will include your [initials/ NHS number/ name/ contact details]. People will use this information to do the research or to check your records to make sure that the research is being done properly.

People who do not need to know who you are will not be able to see your name or contact details. Your data will have a code number instead.

We will keep all information about you safe and secure.

Once we have finished the study, we will keep some of the data so we can check the results. We will write our reports in a way that no-one can work out that you took part in the study. Once we have finished the study, we will keep the data for 5 years so we can check the results again if needed.

Anonymous results may be shared with other researchers or commercial partners. It will not be possible for the data to identify you and your personal data will not be shared

What are your choices about how your information is used?

You can stop being part of the study at any time, without giving a reason, but we will keep information about you that we already have.

Where can you find out more about how your information is used?

You can find out more about how we use your information:

- at www.hra.nhs.uk/information-about-patients/
- our leaflet available from: www.guysandstthomas.nhs.uk/research/patients/use-of-data.aspx (For GSTT) and www.kcl.ac.uk/research/support/research-ethics/kings-college-london-statement-on-use-of-personal-data-in-research (for KCL)
- by asking one of the research team (contact details included below)
- by contacting the Data Protection Officer: (For GSTT: Nick Murphy-O'Kane DPO@gstt.nhs.uk; For KCL: Albert Chan info-compliance@kcl.ac.uk)

Remident Summary Trial Patient Information Leaflet

IRAS Number: 1003587 Version Number: v1.2

EudraCT Number: 2020-005121-89





Who is organizing and funding the study?

This trial is being organised by a group of dentists/doctors and scientists led by Dr Bryan Kerr, who is a consultant at Guy's and St Thomas' Hospital NHS Foundation Trust, and is also supported by Kings College London. It is funded by PAION, which is a commercial company and anonymised study data will be shared with them.

Who has reviewed the study?

This research has been reviewed by an independent group of people, called a Research Ethics Committee, to protect your safety, rights, wellbeing and dignity. This study has been reviewed and given a favourable opinion by a Research Ethics Committee. The study has also been reviewed by the UK Regulatory Authority, the MHRA (the Medicines and Healthcare products Regulatory Agency).

What will we do with the results?

The study will be registered on an online public database so that the results are clearly available to anyone. We also plan to publish the results in Dental and Anaesthetic journals as well as present the findings at conferences.

What happens if I have any questions, concerns or complaints about the study?

If you have a concern about any aspect of this study, you should ask to speak to the researchers who will do their best to answer your questions Dr Bryan Kerr, 0207 188 6076, bryan.kerr@kcl.ac.uk. If you remain unhappy and wish to complain formally, you can do this through the Guy's and St Thomas' Patients Advice and Liaison Service (PALS) on 020 7188 8801, pals@gstt.nhs.uk.

Contact details:

Chief Investigator details:

Name: Dr Bryan Kerr

Address: Sedation and SPC Dentistry, Floor 26 Tower Wing,

Guys and St Thomas' NHS Foundation Trust Westminster Bridge Road, London, SE1 7EH

If you have any concerns about the way the study is carried out by the study staff, or your rights as a research patient or any other aspects of your care, please contact the person below.

Site PALS Team details:

PALS Lead, Patient Information Team

Address: Ground Floor, Guys and St Thomas' NHS Foundation Trust

Westminster Bridge Road, London, SE1 7EH

Email: pals@gstt.nhs.uk

Remident Summary Trial Patient Information Leaflet

IRAS Number: 1003587 Version Number: v1.2

EudraCT Number: 2020-005121-89